Assessing different sequencing regimens of atezolizumab (atezo) and sipuleucel-T (sipT) in patients who have asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer.

141Background: Combining an immune checkpoint inhibitor with a vaccine may leverage complementary mechanisms of action for treatment of mCRPC. We present a randomized study evaluating atezo (anti P...